Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 8/20 | 0.42 |
| ▸ | CYSLTR1 | Q9Y271 | 8/20 | 0.42 |
| ▸ | SCD | O00767 | 1/20 | 0.40 |
| ▸ | F13A1 | P00488 | 3/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | LTB4R | Q15722 | 5/20 | 0.36 |
| ▸ | LTB4R2 | Q9NPC1 | 5/20 | 0.36 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13956429 | 0.87 | CYSLTR2 (0.39) | CYSLTR2CYSLTR1SCDPPARAALDH1A1 | |
| SCHEMBL4450812 | 0.83 | CA2 (0.35) | CYSLTR2CYSLTR1PPARAALDH1A1LMNA | |
| SCHEMBL4450816 | 0.81 | ALDH1A1 (0.37) | CYSLTR2CYSLTR1SCDF13A1PPARA | |
| SCHEMBL4453277 | 0.79 | LTB4R (0.47) | LTB4RLTB4R2 | |
| SCHEMBL13956434 | 0.79 | LTB4R (0.47) | LTB4RLTB4R2 | |
| SCHEMBL4445395 | 0.78 | SCD (0.40) | CYSLTR2CYSLTR1SCDF13A1PPARA | |
| SCHEMBL2305004 | 0.77 | TYR (0.46) | PPARAALDH1A1LMNAPOLBHIF1A | |
| SCHEMBL4450768 | 0.76 | LTB4R (0.49) | LTB4RLTB4R2 | |
| SCHEMBL4460092 | 0.75 | S1PR1 (0.38) | CYSLTR2CYSLTR1SCDF13A1PPARA | |
| SCHEMBL13971111 | 0.74 | LTB4R (0.44) | LTB4RLTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1583738-B1 | INDENONCARBOXYLIC ACIDS DERIVATIVES AND THEIR USE FOR THE TREATMENT OF AND PREVENTING DIABETES AND DYSLIPIDAEMIA | MERCK PATENT GMBH (DE) | 2017-05-10 | — | — | EP | disclosed |
| US-7482484-B2 | Carboxylic acids and derivatives for the treatment of and preventing diabetes and dyslipidaemia | MERCK PATENT GMBH (DE) | 2009-01-27 | — | — | US | disclosed |
| US-20060111445-A1 | Novel carboxylic acids and derivatives for the treatment of and preventing diabetes and dyslipidaemia | MERCK PATENT GMBH (DE) | 2006-05-25 | — | — | US | disclosed |
| EP-1583738-A1 | INDENONCARBOXYLIC ACIDS DERIVATIVES AND THEIR USE FOR THE TREATMENT OF AND PREVENTING DIABETES AND DYSLIPIDAEMIA | MERCK PATENT GmbH (DE) | 2005-10-12 | — | — | EP | disclosed |
| WO-2004063148-A1 | INDENONCARBOXYLIC ACIDS DERIVATIVES AND THEIR USE FOR THE TREATMENT OF AND PREVENTING DIABETES AND DYSLIPIDAEMIA | MERCK PATENT GMBH (DE) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111445-A1 | Novel carboxylic acids and derivatives for the treatment of and preventing diabetes and dyslipidaemia | NR1H3, LDLR, NR1H2 | CYSLTR2 343/4885CYSLTR1 239/4885SCD 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.